Skip to content
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Neutra Corp. NTRR

12 fiscal years on record · USD · FY2022 reported · SEC filings only
$67,996
▼ 26.1% YoY
$-561,417

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. On January 23, 2018, we entered into an agreement with Artillery Labs to sell and market natural nutraceuticals online.

Written from the business description in Neutra Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 2 August 2024. Every sentence was checked against that document before publication.

Growth

USD 67,996.00
Revenue, FY2022 · full 12-year series below
Revenue $ Net income $
FY2022 · Revenue 67996.0 · Net income -561417.0
40000.080000.0-250000.0-500000.0
20112014201720202022
Compound annual growth
+119.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−826 cents
lost on every revenue dollar
Operating margin Net margin
FY2022 · Operating -437.8% · Net -825.7%
-2000%-4000%-6000%
201120162022
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin51.9%
Operating margin-437.8%
Net margin-825.7%
EBITDAUSD -218,769.00

Cash & shareholders

·
returned in FY2022 · dividends + net buybacks
Free cash flow $
FY2021 · FCF -445842.0
-250000.0-500000.0
201120162022

Total assetsUSD 75,175.00
EquityUSD -773,820.00
CashUSD 1,969.00
Current ratio0.03×

Equity funds -1029% of total assets.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NTRR, 12-year financial record
Metric 202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.0◌◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0◌◌◌◌◌◌◌◌◌
Income tax $B0.0◌0.00.0◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌−0.0−0.0◌◌◌◌◌◌◌◌◌
EPS, diluted $◌◌0.000.00−0.16−0.10−0.41−1.25−3.36−0.13−0.16−0.15
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE % — not applicable: negative equity————————————
Shares out B2.741.781.490.620.030.010.000.000.050.010.000.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 47 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 13 checks were skipped: cost of revenue is not tagged before 2020. Eight checks were skipped: the balance sheet is not tagged before 2011. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inWyoming
Fiscal year endsJanuary 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image